| Market Cap | 360.49M | P/E | - | EPS this Y | 5.90% | Ern Qtrly Grth | - |
| Income | -21.72M | Forward P/E | -64.62 | EPS next Y | 206.20% | 50D Avg Chg | -5.00% |
| Sales | 159.01M | PEG | - | EPS past 5Y | -53.59% | 200D Avg Chg | -13.00% |
| Dividend | N/A | Price/Book | 3.69 | EPS next 5Y | - | 52W High Chg | -39.00% |
| Recommedations | 1.70 | Quick Ratio | 1.85 | Shares Outstanding | 43.69M | 52W Low Chg | 17.00% |
| Insider Own | 5.05% | ROA | -6.84% | Shares Float | 33.46M | Beta | 1.02 |
| Inst Own | 77.27% | ROE | -22.08% | Shares Shorted/Prior | 1.73M/1.40M | Price | 8.40 |
| Gross Margin | 80.42% | Profit Margin | -13.66% | Avg. Volume | 182,104 | Target Price | 13.67 |
| Oper. Margin | -7.44% | Earnings Date | May 7 | Volume | 174,523 | Change | -1.29% |
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
| Cantor Fitzgerald | Overweight | Jan 19, 24 |
| Canaccord Genuity | Buy | Dec 7, 23 |
| Leerink Partners | Outperform | Oct 16, 23 |
| Cantor Fitzgerald | Overweight | Sep 26, 23 |
| Cantor Fitzgerald | Overweight | Aug 22, 23 |
| JMP Securities | Market Outperform | May 10, 23 |
| Canaccord Genuity | Buy | Mar 28, 23 |
| JMP Securities | Market Outperform | Mar 15, 23 |
| Canaccord Genuity | Buy | May 9, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Freitag Gregory Gene | Director Director | Jun 01 | Sell | 8.7 | 41,980 | 365,226 | 290,135 | 06/05/23 |
| Freitag Gregory Gene | Director Director | Jun 01 | Option | 0 | 6,459 | 296,594 | 06/05/23 | |
| MARIANI PETER J | EVP & Chief Financia.. EVP & Chief Financial Officer | Jan 30 | Sell | 9.53 | 42,981 | 409,609 | 61,945 | 02/01/23 |
| MARIANI PETER J | EVP & Chief Financia.. EVP & Chief Financial Officer | Jan 30 | Option | 5.04 | 62,818 | 316,603 | 76,495 | 02/01/23 |
| DeVinney Erick Wayne | VP Peripheral Nerve.. VP Peripheral Nerve Science | Dec 27 | Option | 5.09 | 20,000 | 101,800 | 116,752 | 12/28/22 |
| Freitag Gregory Gene | Director Director | Nov 08 | Sell | 12.50 | 13,000 | 162,500 | 352,583 | 11/10/22 |
| Freitag Gregory Gene | Director Director | Aug 10 | Sell | 9.696 | 8,886 | 86,159 | 365,583 | 08/11/22 |
| Freitag Gregory Gene | Director Director | Aug 04 | Sell | 10.51 | 37,046 | 389,353 | 374,469 | 08/08/22 |
| Freitag Gregory Gene | Director Director | Jul 25 | Option | 3.38 | 83,000 | 280,540 | 441,811 | 07/26/22 |
| Donovan Michael Patrick | VP Operations VP Operations | Feb 22 | Option | 5.27 | 15,000 | 79,050 | 57,453 | 02/24/22 |
| Donovan Michael Patrick | VP Operations VP Operations | Feb 09 | Option | 5.14 | 20,000 | 102,800 | 46,029 | 02/09/21 |
| DeVinney Erick Wayne | VP, Clinical&Transla.. VP, Clinical&Translational Sc | Dec 30 | Sell | 17.81 | 371 | 6,608 | 63,240 | 12/30/20 |
| Donovan Michael Patrick | VP Operations VP Operations | Dec 30 | Sell | 17.81 | 567 | 10,098 | 27,762 | 12/30/20 |
| Zaderej Karen L. | CEO CEO | Dec 22 | Sell | 16.42 | 1,275 | 20,936 | 646,719 | 12/22/20 |
| Friedman Mark Louis | VP,Regulatory & Qual.. VP,Regulatory & Quality | Dec 22 | Sell | 16.42 | 96 | 1,576 | 8,893 | 12/22/20 |